Research programme: multiple sclerosis therapy - Merck Serono
Alternative Names: AS-900004Latest Information Update: 04 Nov 2017
At a glance
- Originator Merck Serono
- Class Proteins
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Switzerland (Parenteral)
- 15 Mar 2011 Preclinical development is ongoing in Switzerland
- 14 Apr 2009 Preclinical development is ongoing Switzerland